Dr. Amanda Cano is currently the head of the Molecular Biology & Biomarkers program of Ace Alzheimer Center Barcelona, and scientific collaborator at the Department of Pharmacology, Toxicology and Therapeutic Chemistry of the Faculty of Pharmacy and Food Sciences of the University of Barcelona. Previously, she was an adjunct professor of Physical Chemistry at the University of Barcelona, and possess the official credentials of Assistant Professor of the National Agency for Evaluation and Accreditation (ANECA) of the Ministry of Science (Spanish government), and the Agency for the Quality of the University System of Catalonia (AQU) (Generalitat of Catalunya).
She graduated from Pharmacy at the University of Salamanca, and obtained her Master’s degree and doctoral degree from the University of Barcelona. She is member of the International Society to Advance Alzheimer’s Research and Treatment (ISTAART, Alzheimer’s Association), the Institute of Nanoscience and Nanotechnology of the University of Barcelona (IN2UB) , Grupo Español de Investigación e Innovación en Vesiculas Extracelulares (GEIVEX), and the Center for Biomedical Research in Neurodegenerative Diseases Network (CIBERNED).
Currently, she has more than 95 scientific publications, has an H index of 32, is the PI of 3 competitive projects, directs 3 doctoral thesis and has participated in 5 competitive European projects, 13 competitive national projects, and 26 clinical trials. Her research focuses on the identification and evaluation of new biomarkers and molecular routes involved in the neuropathological development of the Alzheimer’s disease, through the development of proteomic, lipidomic and metabolomic analysis in representative human’s samples of the different stages of the disease continuum.